留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

ADAM17在胃癌中的研究进展

杨梦娇 袁浩 郑亚 王玉平 郭庆红

杨梦娇, 袁浩, 郑亚, 王玉平, 郭庆红. ADAM17在胃癌中的研究进展[J]. 协和医学杂志, 2024, 15(2): 375-381. doi: 10.12290/xhyxzz.2023-0383
引用本文: 杨梦娇, 袁浩, 郑亚, 王玉平, 郭庆红. ADAM17在胃癌中的研究进展[J]. 协和医学杂志, 2024, 15(2): 375-381. doi: 10.12290/xhyxzz.2023-0383
YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Research Progress of ADAM17 in Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 375-381. doi: 10.12290/xhyxzz.2023-0383
Citation: YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Research Progress of ADAM17 in Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 375-381. doi: 10.12290/xhyxzz.2023-0383

ADAM17在胃癌中的研究进展

doi: 10.12290/xhyxzz.2023-0383
详细信息
    通讯作者:

    郭庆红, E-mail: gqh@lzu.edu.cn

  • 中图分类号: R735.2;[R394.3]

Research Progress of ADAM17 in Gastric Cancer

More Information
  • 摘要: 胃癌是最常见的恶性肿瘤之一,患者多采用手术、放化疗及免疫治疗,但临床疗效及预后欠佳。去整合素-金属蛋白酶(a disintegrin and metalloproteinase,ADAM)17作为ADAMs家族的重要成员,在胃癌组织中的表达显著高于癌旁组织,并通过介导EGFR和TNF-α、TGF-β/Smad、Notch和Wnt、FoxM1-ADAM17以及EGFR/ERK/SP1等信号通路参与胃癌的发生发展,其高表达与预后不良密切相关,提示ADAM17可作为胃癌的生物学指标,预测胃癌发展,有望成为胃癌新的治疗靶点。本文就ADAM17在胃癌发展中的作用机制、治疗及预测研究进展作一综述,以期为胃癌临床诊疗提供新思路。
    作者贡献:杨梦娇负责文献检索和论文撰写;袁浩、郑亚、王玉平负责论文指导;郭庆红负责论文选题及论文修订。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  ADAM17参与胃癌发生发展的信号通路

    Nucleus:细胞核;ADAM17(a disintegrin and metalloprotease 17):去整合素-金属蛋白酶17;TGF-β(transforming growth factor-β):转化生长因子-β;EpCAM(epithelial cell adhesion molecule):上皮细胞黏附分子;EpICD nuclear translocation:上皮细胞黏附分子细胞内结构域核转位;EpICD nuclear complex:上皮细胞黏附分子细胞内结构域核复合体;NRDc(Nardilysin):金属肽酶;TNF-α(tumor necrosis factor-α):肿瘤坏死因子-α;IL-6(inter-leukin-6):白细胞介素-6;JAK(Janus kinase):Janus激酶;STAT3(signal transducer and activator of transcription 3):信号转导因子和转录激活因子3;NICD(Notch intracellular domain):Notch胞内结构域;FoxM1(forkhead box protein M1):叉头框蛋白M1;TGF-α(transforming growth factor-α):转化生长因子-α;EGFR(epithelial growth factor receptor):表皮生长因子受体;ERK(extracellular signal-regulated kinase):细胞外信号调节激酶;REG4(regenerating islet derived protein 4):再生胰岛衍生家族成员4;GPR37(G protein-coupled receptor 37):G蛋白偶联受体37;HB-EGF(heparin-binding epidermal growth factor-like growth factor):肝素结合性表皮生长因子;HB-EGF-CTF(HB-EGF-C-terminal fragment):HB-EGF羧基末端片段

    Figure  1.  Signalling pathway of ADAM17 involved in gastric cancer

  • [1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi:  10.3322/caac.21660
    [2] Qiu H B, Cao S M, Xu R H. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun (Lond), 2021, 41(10): 1037-1048. doi:  10.1002/cac2.12197
    [3] 帕孜来提·亚森, 袁浩, 路红, 等. 胃癌靶向治疗药物临床实验研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 454-461. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL202104016.htm

    Yasen P Z L T, Yuan H, Lu H, et al. Research progress in clinical trials of targeted drugs for gastric cancer[J]. Chin J Clin Pharmacol Ther, 2021, 26(4): 454-461. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL202104016.htm
    [4] Nakamura Y, Kawazoe A, Lordick F, et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm[J]. Nat Rev Clin Oncol, 2021, 18(8): 473-487. doi:  10.1038/s41571-021-00492-2
    [5] Yang G, Cui M Y, Jiang W B, et al. Molecular switch in human diseases-disintegrin and metalloproteinases, Adam17[J]. Aging (Albany NY), 2021, 13(12): 16859-16872.
    [6] Zunke F, Rose-John S. The shedding protease ADAM17: physiology and pathophysiology[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 Pt B): 2059-2070.
    [7] Düsterhöft S, Babendreyer A, Giese A A, et al. Status update on iRhom and ADAM17: it's still complicated[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(10): 1567-1583. doi:  10.1016/j.bbamcr.2019.06.017
    [8] Babendreyer A, Rojas-González D M, Giese A A, et al. Differential induction of the ADAM17 regulators iRhom1 and 2 in endothelial cells[J]. Front Cardiovasc Med, 2020, 7: 610344. doi:  10.3389/fcvm.2020.610344
    [9] Düsterhöft S, Lokau J, Garbers C. The metalloprotease ADAM17 in inflammation and cancer[J]. Pathol Res Pract, 2019, 215(6): 152410. doi:  10.1016/j.prp.2019.04.002
    [10] Schumacher N, Rose-John S. ADAM17 orchestrates Interleukin-6, TNFα and EGF-R signaling in inflammation and cancer[J]. Biochim Biophys Acta Mol Cell Res, 2022, 1869(1): 119141. doi:  10.1016/j.bbamcr.2021.119141
    [11] Meng X C, Hu B S, Hossain M M, et al. ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation[J]. Int J Oncol, 2016, 49(2): 682-690. doi:  10.3892/ijo.2016.3536
    [12] Jia D Y, Underwood J, Xu Q P, et al. NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer[J]. Oncol Lett, 2019, 17(6): 4914-4920.
    [13] Rogmans C, Kuhlmann J D, Hugendieck G, et al. ADAM17-a potential blood-based biomarker for detection of early-stage ovarian cancer[J]. Cancers (Basel), 2021, 13(21): 5563. doi:  10.3390/cancers13215563
    [14] Schmidt S, Schumacher N, Schwarz J, et al. ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling[J]. J Exp Med, 2018, 215(4): 1205-1225. doi:  10.1084/jem.20171696
    [15] Xiao L J, Lin P, Lin F, et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion[J]. Int J Oncol, 2012, 40(5): 1714-1724.
    [16] Mishra H K, Pore N, Michelotti E F, et al. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells[J]. Cancer Immunol Immunother, 2018, 67(9): 1407-1416. doi:  10.1007/s00262-018-2193-1
    [17] Saha N, Xu K, Zhu Z Y, et al. Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells[J]. Transl Oncol, 2022, 15(1): 101265. doi:  10.1016/j.tranon.2021.101265
    [18] Kanda K, Komekado H, Sawabu T, et al. Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF-α[J]. EMBO Mol Med, 2012, 4(5): 396-411. doi:  10.1002/emmm.201200216
    [19] Ebi M, Kataoka H, Shimura T, et al. TGFβ induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells[J]. Biochem Biophys Res Commun, 2010, 402(3): 449-454. doi:  10.1016/j.bbrc.2010.09.130
    [20] Sun J B, Jiang J L, Lu K Y, et al. Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-α signalling pathways[J]. Mol Cell Biochem, 2017, 426(1/2): 17-26.
    [21] Kalluri R, Weinberg R A. The basics of epithelial-mesenchymal transition[J]. J Clin Invest, 2009, 119(6): 1420-1428. doi:  10.1172/JCI39104
    [22] Tsai J H, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis[J]. Genes Dev, 2013, 27(20): 2192-2206. doi:  10.1101/gad.225334.113
    [23] Brabletz S, Schuhwerk H, Brabletz T, et al. Dynamic EMT: a multi-tool for tumor progression[J]. EMBO J, 2021, 40(18): e108647. doi:  10.15252/embj.2021108647
    [24] Xu M, Zhou H L, Zhang C L, et al. ADAM17 promotes epithelial-mesenchymal transition via TGF-β/Smad pathway in gastric carcinoma cells[J]. Int J Oncol, 2016, 49(6): 2520-2528. doi:  10.3892/ijo.2016.3744
    [25] 周海浪. ADAM17通过TGF-β/Smad通路促进胃癌细胞增殖、迁移和侵袭[D]. 镇江: 江苏大学, 2017.

    Zhou H L. ADAM17 promotes the proliferation, migration and invasion via TGF-β/Smad pathway in gastric carcinoma cells[D]. Zhenjiang: Jiangsu University, 2017.
    [26] Gires O, Pan M, Schinke H, et al. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?[J]. Cancer Metastasis Rev, 2020, 39(3): 969-987. doi:  10.1007/s10555-020-09898-3
    [27] Warneke V S, Behrens H M, Haag J, et al. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis[J]. Br J Cancer, 2013, 109(8): 2217-2227. doi:  10.1038/bjc.2013.536
    [28] Du X, Cheng Z, Wang Y H, et al. Role of Notch signaling pathway in gastric cancer: a meta-analysis of the literature[J]. World J Gastroenterol, 2014, 20(27): 9191-9199.
    [29] Yao Y Z, Ni Y, Zhang J W, et al. The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets[J]. Oncotarget, 2017, 8(32): 53839-53853. doi:  10.18632/oncotarget.17809
    [30] Xu Z, Ran J, Gong K, et al. LncRNA SUMO1P3 regulates the invasion, migration and cell cycle of gastric cancer cells through Wnt/β-catenin signaling pathway[J]. J Recept Signal Transduct Res, 2021, 41(6): 574-581. doi:  10.1080/10799893.2020.1836494
    [31] Peng Y, Xu Y D, Zhang X J, et al. A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression[J]. Mol Cancer, 2021, 20(1): 158. doi:  10.1186/s12943-021-01457-w
    [32] Li W, Wang D G, Sun X, et al. ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways[J]. Int J Mol Med, 2019, 43(2): 914-926.
    [33] Li Q, Zhang N, Jia Z L, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression[J]. Cancer Res, 2009, 69(8): 3501-3509. doi:  10.1158/0008-5472.CAN-08-3045
    [34] Yang L, Cui M, Zhang L, et al. FOXM1 facilitates gastric cancer cell migration and invasion by inducing Cathepsin D[J]. Oncotarget, 2017, 8(40): 68180-68190. doi:  10.18632/oncotarget.19254
    [35] 房文铮. FoxM1调控ADAM17促进胃癌发生发展的机制研究[D]. 上海: 第二军医大学, 2014.

    Fang W Z. FoxMl regulates ADAM17 in promoting the development of gastric cancer[D]. Shanghai: The Second Military Medical University, 2014.
    [36] Fang W Z, Qian J X, Wu Q, et al. ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma[J]. J Surg Res, 2017, 220: 223-233. doi:  10.1016/j.jss.2017.06.032
    [37] Wang H X, Hu L, Zang M D, et al. REG4 promotes peritoneal metastasis of gastric cancer through GPR37[J]. Oncotarget, 2016, 7(19): 27874-27888. doi:  10.18632/oncotarget.8442
    [38] Liu X, Yao L, Qu J K, et al. Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression[J]. J Transl Med, 2021, 19(1): 325. doi:  10.1186/s12967-021-03012-z
    [39] Ishimoto T, Miyake K, Nandi T, et al. Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells[J]. Gastroenterology, 2017, 153(1): 191-204.e16. doi:  10.1053/j.gastro.2017.03.046
    [40] Chen J T, Yao K H, Hua L, et al. MiR-338-3p inhibits the proliferation and migration of gastric cancer cells by targeting ADAM17[J]. Int J Clin Exp Pathol, 2015, 8(9): 10922-10928.
    [41] AmeliMojarad M, AmeliMojarad M, Pourmahdian A. Cir-cular RNA circ_0051620 sponges miR-338-3p and regulates ADAM17 to promote the gastric cancer progression[J]. Pathol Res Pract, 2022, 233: 153887. doi:  10.1016/j.prp.2022.153887
    [42] Zhang T C, Zhu W G, Huang M D, et al. Prognostic value of ADAM17 in human gastric cancer[J]. Med Oncol, 2012, 29(4): 2684-2690. doi:  10.1007/s12032-011-0125-4
    [43] Shou Z X, Jin X, Zhao Z S. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer[J]. Ann Surg, 2012, 256(6): 1014-1022. doi:  10.1097/SLA.0b013e3182592f56
    [44] Aydin D, Bilici A, Yavuzer D, et al. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy[J]. Clin Transl Oncol, 2015, 17(8): 604-611. doi:  10.1007/s12094-015-1283-1
    [45] Ni P, Yu M Y, Zhang R G, et al. Prognostic significance of ADAM17 for gastric cancer survival: a meta-analysis[J]. Medicina (Kaunas), 2020, 56(7): 322. doi:  10.3390/medicina56070322
  • 加载中
图(1)
计量
  • 文章访问数:  48
  • HTML全文浏览量:  6
  • PDF下载量:  22
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-08-19
  • 录用日期:  2023-11-28
  • 刊出日期:  2024-03-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!